Canadian Diabetes Association and Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings, physicians will get a first-time look at more detailed results from a phase-3b clinical study Liraglutide Effect and Action in Diabetes (LEAD) 6 comparing the investigational new drug liraglutide to exenatide. The study showed that liraglutide, a human GLP-1 analog administered once daily was significantly more effective at improving blood glucose control (as measured by HbA1c) than exenatide, a GLP-1 mimetic administered twice daily.
The details can be read here.
No comments:
Post a Comment